the classical drugs used to decrease prolactin production and release from the pituitary, do not affect production of prolactin in nonpituitary tissues Prolactin-receptor antagonists are ...

The Food and Drug Administration (FDA ... ST316, an investigational β-catenin and BCL9 interaction peptide antagonist, inhibits the Wnt enhanceosome protein complex formulation that leads ...

Spironolactone is a nonselective aldosterone antagonist, and eplerenone is selective to the aldosterone receptor. Although numerous clinical trials have evaluated the efficacy of each drug ...

Researchers from Gedeon Richter plc have reported the discovery of novel dual vasopressin V1A/V2 antagonist, drug candidates for arginine vasopressin (AVP) for the potential treatment of hyponatremia.

Billings, compares the state’s purchase of overdose reversal drugs like Narcan from companies that have contributed to the ...

The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

Kennedy Jr. might inflict on one of his favorite targets, the Food and Drug Administration, if he is confirmed as secretary of health and human services. By proposing Kennedy, the political family ...